Aurinia Pharmaceuticals AUPH
$ 7.21
0.0%
Quarterly report 2024-Q2
added 08-01-2024
Aurinia Pharmaceuticals Balance Sheet 2011-2024 | AUPH
Annual Balance Sheet Aurinia Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
27.7 M | -86 M | -223 M | - | -306 M | -118 M | -166 M | -39.6 M | -5.76 M | -22.7 M | -1.82 M | -149 K | -5.84 M |
Long Term Debt |
75.5 M | 7.15 M | 7.68 M | - | - | - | - | - | - | - | - | - | 35.3 K |
Long Term Debt Current |
989 K | 936 K | 1.06 M | 788 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 41.9 M | 26 M | 16 M | 13.1 M | 9.99 M | 4.44 M | 3.8 M | 2.61 M | 5.78 M |
Total Current Liabilities |
77.2 M | 46.1 M | 40.6 M | 32 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
170 M | 65.4 M | 64.3 M | 55.9 M | 53.2 M | 33.3 M | 24.1 M | 21 M | 13.6 M | 7.27 M | 9.84 M | 6.28 M | 7.91 M |
Deferred Revenue |
4.81 M | 3.15 M | 190 K | - | 118 K | 118 K | 118 K | 118 K | 168 K | 217 K | 227 K | 340 K | 1.22 M |
Retained Earnings |
-942 M | -864 M | -756 M | -575 M | -540 M | -416 M | -352 M | -281 M | -258 M | -236 M | -205 M | -217 M | -202 M |
Total Assets |
548 M | 471 M | 543 M | 464 M | 327 M | 146 M | 190 M | 57 M | 33.6 M | 52.4 M | 23.1 M | 4.16 M | 14.3 M |
Cash and Cash Equivalents |
48.8 M | 94.1 M | 232 M | 272 M | 306 M | 118 M | - | - | - | - | - | - | - |
Book Value |
378 M | 405 M | 479 M | 408 M | 274 M | 113 M | 166 M | 36 M | 20 M | 45.1 M | 13.3 M | -2.12 M | 6.41 M |
Total Shareholders Equity |
378 M | 405 M | 479 M | 408 M | 299 M | 136 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aurinia Pharmaceuticals
2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
64.9 M | 67.5 M | 75.5 M | 72.2 M | 79.4 M | 6.99 M | 7.15 M | 7.27 M | - | 7.56 M | 7.68 M | 7.8 M | 7.82 M | 7.81 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
159 M | 157 M | 170 M | 163 M | 157 M | 61.4 M | 65.4 M | 64.9 M | - | 58.8 M | 64.3 M | 61.9 M | 54 M | 46.8 M | 55.9 M | 55.9 M | 55.9 M | 55.9 M | 25.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
4.37 M | 4.91 M | 4.81 M | 4.66 M | 3.23 M | 3.16 M | 3.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-952 M | -953 M | -942 M | -915 M | -902 M | -891 M | -864 M | -838 M | - | -794 M | -756 M | -723 M | -673 M | -626 M | -575 M | -575 M | -575 M | -575 M | -472 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
524 M | 517 M | 548 M | 555 M | 549 M | 452 M | 471 M | 488 M | - | 507 M | 543 M | 360 M | 386 M | 417 M | 464 M | 464 M | 464 M | 464 M | 324 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
33.3 M | 63.9 M | 48.9 M | 45.6 M | 81.4 M | 88.3 M | 94.2 M | 85.3 M | 151 M | 132 M | 232 M | 57.6 M | 122 M | 157 M | 272 M | 272 M | 272 M | 272 M | 306 M | - | - | - | 118 M | - | - | - | 166 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
365 M | 359 M | 378 M | 392 M | 392 M | 390 M | 405 M | 423 M | - | 448 M | 479 M | 298 M | 332 M | 370 M | 408 M | 408 M | 408 M | 408 M | 299 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
365 M | 359 M | 378 M | 392 M | 392 M | 390 M | 405 M | 423 M | 424 M | 448 M | 479 M | 298 M | 332 M | 370 M | 408 M | 408 M | 408 M | 408 M | 299 M | - | - | - | 136 M | - | - | - | 178 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency